223 related articles for article (PubMed ID: 31733403)
1. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study.
Mulder FI; van Es N; Kraaijpoel N; Di Nisio M; Carrier M; Duggal A; Gaddh M; Garcia D; Grosso MA; Kakkar AK; Mercuri MF; Middeldorp S; Royle G; Segers A; Shivakumar S; Verhamme P; Wang T; Weitz JI; Zhang G; Büller HR; Raskob G
Thromb Res; 2020 Jan; 185():13-19. PubMed ID: 31733403
[TBL] [Abstract][Full Text] [Related]
2. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
Kraaijpoel N; Di Nisio M; Mulder FI; van Es N; Beyer-Westendorf J; Carrier M; Garcia D; Grosso M; Kakkar AK; Mercuri MF; Middeldorp S; Hernandez CR; Santamaria A; Schwocho L; Segers A; Verhamme P; Wang TF; Weitz JI; Zhang G; Zwicker JI; Büller HR; Raskob GE
Thromb Haemost; 2018 Aug; 118(8):1439-1449. PubMed ID: 30060256
[TBL] [Abstract][Full Text] [Related]
3. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
Di Nisio M; van Es N; Carrier M; Wang TF; Garcia D; Segers A; Weitz J; Buller H; Raskob G
J Thromb Haemost; 2019 Nov; 17(11):1866-1874. PubMed ID: 31271705
[TBL] [Abstract][Full Text] [Related]
4. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Raskob GE; van Es N; Verhamme P; Carrier M; Di Nisio M; Garcia D; Grosso MA; Kakkar AK; Kovacs MJ; Mercuri MF; Meyer G; Segers A; Shi M; Wang TF; Yeo E; Zhang G; Zwicker JI; Weitz JI; Büller HR;
N Engl J Med; 2018 Feb; 378(7):615-624. PubMed ID: 29231094
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of cancer-associated venous thromboembolism].
Di Nisio M
G Ital Cardiol (Rome); 2018 Sep; 19(9 Suppl 1):7S-12S. PubMed ID: 30284557
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial.
Nakamura M; Wang YQ; Wang C; Oh D; Yin WH; Kimura T; Miyazaki K; Abe K; Mercuri M; Lee LH; Segers A; Büller H
J Thromb Haemost; 2015 Sep; 13(9):1606-14. PubMed ID: 26179767
[TBL] [Abstract][Full Text] [Related]
7. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
Brekelmans MP; Ageno W; Beenen LF; Brenner B; Buller HR; Chen CZ; Cohen AT; Grosso MA; Meyer G; Raskob G; Segers A; Vanassche T; Verhamme P; Wells PS; Zhang G; Weitz JI
Lancet Haematol; 2016 Sep; 3(9):e437-45. PubMed ID: 27570090
[TBL] [Abstract][Full Text] [Related]
8. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
[TBL] [Abstract][Full Text] [Related]
9. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
Raskob G; Ageno W; Cohen AT; Brekelmans MP; Grosso MA; Segers A; Meyer G; Verhamme P; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
Lancet Haematol; 2016 May; 3(5):e228-36. PubMed ID: 27132697
[TBL] [Abstract][Full Text] [Related]
10. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
van Es N; Di Nisio M; Bleker SM; Segers A; Mercuri MF; Schwocho L; Kakkar A; Weitz JI; Beyer-Westendorf J; Boda Z; Carrier M; Chlumsky J; Décousus H; Garcia D; Gibbs H; Kamphuisen PW; Monreal M; Ockelford P; Pabinger I; Verhamme P; Grosso MA; Büller HR; Raskob GE
Thromb Haemost; 2015 Nov; 114(6):1268-76. PubMed ID: 26271200
[TBL] [Abstract][Full Text] [Related]
11. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
Medina A; Raskob G; Ageno W; Cohen AT; Brekelmans MPA; Chen CZ; Grosso MA; Mercuri MF; Segers A; Verhamme P; Vanassche T; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
Thromb Haemost; 2017 Dec; 117(12):2406-2414. PubMed ID: 29212128
[TBL] [Abstract][Full Text] [Related]
12. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study.
Scheres L; Brekelmans M; Ageno W; Ay C; Büller HR; Eichinger S; Hutten BA; Klok FA; Middeldorp S; Schreiber K; Stach K; Blondon M; Delluc A
BJOG; 2018 Nov; 125(12):1581-1589. PubMed ID: 29940089
[TBL] [Abstract][Full Text] [Related]
13. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
14. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.
Ay C; Beyer-Westendorf J; Pabinger I
Ann Oncol; 2019 Jun; 30(6):897-907. PubMed ID: 30918939
[TBL] [Abstract][Full Text] [Related]
15. The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients.
Abdel-Razeq H; Finianos A; Taher AT
Expert Rev Hematol; 2018 Jun; 11(6):487-494. PubMed ID: 29791257
[TBL] [Abstract][Full Text] [Related]
16. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
Di Nisio M; Raskob G; Büller HR; Grosso MA; Zhang G; Winters SM; Cohen A
Thromb Haemost; 2017 Apr; 117(4):784-793. PubMed ID: 28151543
[TBL] [Abstract][Full Text] [Related]
17. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.
Verhamme P; Wells PS; Segers A; Ageno W; Brekelmans MP; Cohen AT; Meyer G; Grosso MA; Raskob G; Weitz JI; Zhang G; Buller H
Thromb Haemost; 2016 Sep; 116(4):747-53. PubMed ID: 27440518
[TBL] [Abstract][Full Text] [Related]
18. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial.
Vanassche T; Verhamme P; Wells PS; Segers A; Ageno W; Brekelmans MPA; Chen CZ; Cohen AT; Grosso MA; Medina AP; Mercuri MF; Winters SM; Zhang G; Weitz JI; Raskob GE; Büller HR
Thromb Res; 2018 Feb; 162():7-14. PubMed ID: 29248859
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
Brekelmans MP; Bleker SM; Bauersachs R; Boda Z; Büller HR; Choi Y; Gallus A; Grosso MA; Middeldorp S; Oh D; Raskob G; Schwocho L; Cohen AT
Thromb Haemost; 2016 Jul; 116(1):155-61. PubMed ID: 27010092
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of incidental venous thromboembolism in cancer patients.
Mulder FI; Di Nisio M; Ay C; Carrier M; Bosch FTM; Segers A; Kraaijpoel N; Grosso MA; Zhang G; Verhamme P; Wang TF; Weitz JI; Middeldorp S; Raskob G; Beenen LFM; Büller HR; van Es N
Eur Respir J; 2020 Feb; 55(2):. PubMed ID: 31727694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
